Full Press Release Details
CERTAIN IDENTIFIED INFORMATION
HAS BEEN EXCLUDED FROM THIS EXHIBIT
BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS
AS PRIVATE OR CONFIDENTIAL.
THE OMISSIONS HAVE BEEN INDICATED BY "[***]".
TERMINATION AGREEMENT
This Termination Agreement
("Termination Agreement") by
Both Alvotech and Stada are sometimes collectively
referred to in this Termination Agreement as the "Parties", and each may be referred to in the singular as a "Party".
WHEREAS Alvotech and Stada
have agreed to terminate the Vedolizumab Agreement (defined below) on the terms and conditions set out in this Termination Agreement.
having capitalised first letters as used in this Termination Agreement and not specifically defined below shall have the same meanings
as given to these same definitions in the Vedolizumab Agreement. In addition, the following definitions shall apply for the purpose
of this Termination Agreement:
or subcontractors of Stada or its Affiliates to the extent necessary for the manufacture, marketing, use, or sale of the Vedolizumab
Product in the Territory. Such license granted under this Clause 4.5 shall exclude rights to any trademarks, trade dress of use
of the company names of Stada or its Affiliates.
IN WITNESS, the parties have caused this
Termination Agreement to be executed by their duly authorised representatives on the date first written above.
| For and behalf of STADA Arzneimittel AG /s/ Peter Goldschmidt | For and behalf of STADA Arzneimittel AG /s/ Bryan Kim |
| Name: Peter Goldschmidt Title: CEO | Name: Bryan Kim Title: EVP Speciality |
| Bad Vilbel, 19 May 2023 | Bad Vilbel, 19 May 2023 |
| For and behalf of Alvotech hf. /s/ Robert Wessman | For and behalf of STADA Arzneimittel AG |
| Name: Robert Wessman Title: CEO and Chairman | Name: Title: |
| Reykjav k, 19 May 2023 | Bad Vilbel, 19 May 2023 |